Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

In a recent study of 35 World Trade Center first responders in the Journal of Alzheimer’s Disease, lead author Sean Clouston, ...

Patients with ATTR-PN have a high rate of comorbidities and substantial direct healthcare and economic burdens, a study found.